H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the shares after the interim analysis of the Phase 3 ATRISTRY-7 study failed to show a statistically significant overall survival benefit over investigator’s choice chemotherapy in platinum-resistant ovarian cancer. The firm says the key investor focus for nemvaleukin now shifts to the extent of read-through to the upcoming data in both mucosal and cutaneous melanoma. H.C. Wainwright is “hesitant to completely rule out a pathway forward” for nemvaleukin.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MURA:
- Mural Oncology halting progress of nemvaleukin trial in ovarian cancer
- Mural Oncology downgraded to Hold from Buy at JonesResearch
- Mural Oncology downgraded to Outperform from Strong Buy at Raymond James
- Raymond James downgrades Mural Oncology after ovarian cancer failure
- Mural Oncology downgraded to Equal Weight from Overweight at Morgan Stanley